Based in Berlin, Paul W. Beyvers GmbH specializes as a contract manufacturer in the development, production, analytics, filling, and packaging of liquid and semi-solid dosage forms. The company manufactures pharmaceuticals, medical devices, and cosmetics in compliance with strict GMP guidelines. With an average workforce of 93 employees, the business focuses on a balanced product structure through targeted diversification. Its operations include supporting new customers in product development as well as manufacturing for existing client relationships.
Die Herstellung und der Vertrieb von Arzneimitteln, Medizinprodukten, Nahrungsergänzungsmitteln und Kosmetika aller Art.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 28348 (as of 24 October 2026)
| Name | Type | City |
|---|---|---|
| Michael Gilster | Geschäftsführer(in) | Weinheim |
| Robert Weigl | Geschäftsführer(in) | Rangsdorf |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 28348 (as of 24 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 18.11.2025 | Business Address Change | Schaffhausener Straße 26-34, 12099 Berlin |
| 17.08.2020 | Business Purpose Update | Die Herstellung und der Vertrieb von Arzneimitteln, Medizinprodukten, Nahrungsergänzungsmitteln und Kosmetika aller Art. |
| 17.08.2020 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 28348 (as of 24 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2020 | Rohergebnis€9.6M2 | €1,014,842 | €16,459,108 | — |
| 2019 | Rohergebnis€10.5M2 | €2,222,492 | €34,786,958 | — |
| 2018 | Rohergebnis€10.8M2 | €2,843,230 | €32,320,970 | — |
| 2017 | Rohergebnis€9.9M2 | €2,130,909 | €29,208,074 | — |
| 2016 | Rohergebnis€9.8M2 | €2,275,851 | €27,356,130 | — |
| 2015 | Rohergebnis€9M2 | €2,120,428 | €24,999,961 | — |
| 2014 | Rohergebnis€8.3M2 | €1,723,898 | €22,706,860 | — |
| 2013 | Rohergebnis€7.8M2 | €1,600,714 | €21,141,693 | — |
| 2012 | Rohergebnis€8.5M2 | €2,590,636 | €19,491,566 | — |
| 2011 | Rohergebnis€7.4M2 | €1,577,081 | €17,153,133 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 28348 (as of 24 October 2026)
Gebr. Ewald GmbH
Schleusingen · Herstellung von Körperpflegemitteln und Duftstoffen
SWIF GmbH South West International Fragrance
Kaiserslautern · Herstellung von Körperpflegemitteln und Duftstoffen
Dr. Hobein (Nachf.) GmbH Medizinische Hautpflege
Meckenheim · Herstellung von Körperpflegemitteln und Duftstoffen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,652,101 | 83.2% |
| Depreciation | €856,689 | 15.3% |
| Interest & Similar | €85,127 | 1.5% |
